ZA932308B - Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection - Google Patents

Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Info

Publication number
ZA932308B
ZA932308B ZA932308A ZA932308A ZA932308B ZA 932308 B ZA932308 B ZA 932308B ZA 932308 A ZA932308 A ZA 932308A ZA 932308 A ZA932308 A ZA 932308A ZA 932308 B ZA932308 B ZA 932308B
Authority
ZA
South Africa
Prior art keywords
hiv
prevention
treatment
monoclonal antibodies
recombinant human
Prior art date
Application number
ZA932308A
Other languages
English (en)
Inventor
Emilio A Emini
Anthony J Conley
George E Mark
L Syd Johnson
David S Pfarr
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA932308B publication Critical patent/ZA932308B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA932308A 1992-04-01 1993-03-31 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection ZA932308B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01

Publications (1)

Publication Number Publication Date
ZA932308B true ZA932308B (en) 1994-09-30

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932308A ZA932308B (en) 1992-04-01 1993-03-31 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Country Status (19)

Country Link
EP (1) EP0577243A3 (xx)
JP (1) JPH06217791A (xx)
KR (1) KR950700761A (xx)
CN (1) CN1081716A (xx)
AU (2) AU3928593A (xx)
BG (1) BG99074A (xx)
CA (1) CA2093099A1 (xx)
CZ (1) CZ239694A3 (xx)
FI (1) FI944561A0 (xx)
HU (1) HUT70461A (xx)
IL (1) IL105145A0 (xx)
MX (1) MX9301858A (xx)
NO (1) NO943653L (xx)
NZ (1) NZ251582A (xx)
RU (1) RU94045907A (xx)
SK (1) SK116294A3 (xx)
WO (1) WO1993019785A1 (xx)
YU (1) YU22693A (xx)
ZA (1) ZA932308B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511291A (en) * 1998-10-30 2003-08-29 Novozymes As A method for selecting a protein variant that has reduced immunogenicity as compared with the parent or wild-type protein
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
US8332159B2 (en) 2003-02-20 2012-12-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing efficacy of preparation of monoclonal antibody
WO2009029569A1 (en) * 2007-08-24 2009-03-05 Novartis Vaccines And Diagnostics Inc. Hiv env proteins with modifications in the v3 loop
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2015117008A2 (en) * 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
TWI733652B (zh) * 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
EP3194401B1 (en) 2014-09-16 2020-10-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE122237T1 (de) * 1987-05-29 1995-05-15 Tanox Biosystems Inc Hiv-1 neutralisierende monoklonale antikörper.
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
CA2058630A1 (en) * 1989-06-05 1990-12-06 Charles F. Scott, Jr. Human monoclonal antibodies to hiv-1 mn gp 120
EP0535154A4 (en) * 1990-06-15 1993-12-01 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
CA2128879A1 (en) * 1992-01-29 1993-08-05 Marie E. Beckner Aamp-1, a protein with local homologies to hiv-1 env and nef proteins

Also Published As

Publication number Publication date
NO943653D0 (no) 1994-09-30
AU3563093A (en) 1993-10-07
RU94045907A (ru) 1996-11-10
EP0577243A3 (en) 1994-11-02
NO943653L (no) 1994-11-30
SK116294A3 (en) 1996-11-06
HUT70461A (en) 1995-10-30
FI944561A (fi) 1994-09-30
IL105145A0 (en) 1993-07-08
CA2093099A1 (en) 1993-10-02
NZ251582A (en) 1997-07-27
JPH06217791A (ja) 1994-08-09
AU3928593A (en) 1993-11-08
YU22693A (sh) 1997-01-08
WO1993019785A1 (en) 1993-10-14
KR950700761A (ko) 1995-02-20
AU658987B2 (en) 1995-05-04
FI944561A0 (fi) 1994-09-30
HU9402824D0 (en) 1994-11-28
CN1081716A (zh) 1994-02-09
MX9301858A (es) 1994-03-31
EP0577243A2 (en) 1994-01-05
CZ239694A3 (en) 1995-07-12
BG99074A (en) 1995-11-30

Similar Documents

Publication Publication Date Title
EP0831873A4 (en) COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS
GB9019812D0 (en) Novel antibodies for treatment and prevention of infection in animals and man
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
EP0584558A3 (en) Composition for suppressing infection and growth of the human immunodeficiency virus using an iron-binding protein.
KR890002547A (ko) Hiv 감염의 치료 및 진단용 모노클로날항체 및 펩티드
AU4028895A (en) Vaccine and treatment method of Human Immunodeficiency Virus
IL105145A0 (en) Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection
ZA913949B (en) Diagnosis and treatment of viral hepatitis
GB9304746D0 (en) Treatment of viral infections
EP0628056A4 (en) TARGETED HUMAN IMMUNGLOBULINE TO PREVENT AND TREAT STAPHYLOCOCCEN INFECTIONS.
ZA9510108B (en) Composition and method for prevention and treatment of HIV-1 infection
EP0382551A3 (en) Prevention and treatment of herpes virus infections
AU591017B2 (en) Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient
ZA946489B (en) Novel treatment of upper respiratory tract infections
EP0655919A4 (en) TREATMENT OF VIRAL INFECTIONS IN MAN.
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
GB9216360D0 (en) Treatment of blood
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
PH27412A (en) Method of treatment of human immunodeficiency virus
ZA941471B (en) Treatment of viral infections
IE880770L (en) Treatment of viral infections
NZ233973A (en) Treatment of viral and/or bacterial infections
NZ231322A (en) Treatment of viral and/or bacterial infections
IE892991L (en) Treatment of viral infections
AU6974796A (en) Treatment and prevention of hiv infection and aids with sarcoid-derived antigens